Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AIP 303
- Development stage
- Preclinical
- Lead developer
- AIP
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
AIP 303 is a therapeutic radiopharmaceutical candidate under development by Advanced Innovative Partners (AIP) for the treatment of breast cancer. As a targeted radionuclide therapy, it is designed to selectively deliver cytotoxic radiation to malignant cells, thereby inducing DNA damage and cell death while sparing healthy tissue. Currently in the preclinical stage, AIP 303 is part of a broader oncology pipeline focused on both diagnostic imaging and therapeutic applications of radiopharmaceuticals. The specific molecular target and the radioisotope utilized in the formulation have not been disclosed by the developer.
Beyond the preview
Go deeper on AIP 303.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AIP 303.